Diabetes

News

AstraZeneca builds in obesity with $2bn+ Eccogene deal

AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist

News

NICE backs 'artifical pancreas' tech for type 1 diabetics

An independent NICE committee has recommended that thousands of people with type 1 diabetes who can’t control the condition with current glucose monitoring and insulin pum

News

Novo Nordisk shrugs off supply issues with record sales

Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt

News

Bayer launches support tool for diabetic kidney disease

Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression t

News

Novo Nordisk’s semaglutide aces another outcomes trial

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft

News

Roche app relieves diabetes distress in clinical trial

A digital health application (DiGA) has been shown to relieve the distress that patients can experience when managing diabetes, which can compromise their care, in a rando

AstraZeneca builds in obesity with $2bn+ Eccogene deal

NICE backs 'artifical pancreas' tech for type 1 diabetics

Novo Nordisk shrugs off supply issues with record sales

Bayer launches support tool for diabetic kidney disease

Novo Nordisk’s semaglutide aces another outcomes trial

Roche app relieves diabetes distress in clinical trial

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Diabetes

Editor's Picks